Nicotine Pouches

ApprovedSmall molecule

JJohns Hopkins University

Nicotine Pouches is one of 29 small molecule programs targeting Smoker. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SmokerRecruiting

Smoking CessationActive, not recruiting

SmokerApproved

Recruiting

Smoking CessationPhase 1

Active, not recruiting

Competition

Competitive Landscape

154 competitors in Smoking Cessation

#DrugCompanyPhaseTrials

Wellbutrin

GSK

Phase 3

5 2

Chantix

Pfizer

Phase 3

3 3

Ozempic

Novo Nordisk

Phase 3

2 4

Topamax

WWim Janssens

Phase 3

3 5

Rimonabant

Sanofi

Phase 3

5 6

Lopid

Pfizer

Phase 2

1 7

Pharmacotherapy

UUniversity of Pittsburgh

Phase 3

1 8

Standard Treatment

Boehringer Ingelheim

Phase 3

1 9

Nicotine Pouches

JJohns Hopkins University

Approved

1 10

Selincro

IIndivior Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Acute

NCT07128329

Q3 2029

ApprovedRecruiting

Smoker

NCT06595459

Clinical

Trials by Indication[1]

Smoking Cessation1 trial

Electronic Cigarettes and Nicotine Pouches for Smoking Cessation

Unknown status·AAlternative Research Initiative·Phase 1·NCT05715164·600 enrolled

Acute1 trial

Acute Effects of Oral Nicotine Pouches

Recruiting·JJohns Hopkins University·Phase 1·NCT07128329·120 enrolled

Smoker1 trial

A Randomized Comparative Effectiveness Trial of Nicotine Pouches for Cigarette Substitution: A Question of Public Health

Recruiting·UUniversity of Wisconsin, Madison·Approved·NCT06595459·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Nicotine Pouches. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nicotine Pouches compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nicotine Pouches. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johns Hopkins University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: JJohns Hopkins University

Nicotine Pouches

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2029

Trials by Indication[1]

Smoking Cessation1 trial

Acute1 trial

Smoker1 trial

References

Drug Info

Quick Facts

Related News